文献速递临床试验与 GCP流行病学与生物统计

肯尼亚年轻女性单剂HPV疫苗接种的持久性:随机对照试验3年结果

Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results.
PubMed 文献 · Nat Med · 2023-12-04

在肯尼亚开展的多中心随机双盲对照试验中,2275名15-20岁健康女性随机接受二价(n=760)、九价(n=758)或对照(n=757)疫苗。随访3年,九价疫苗对HPV 16/18持续感染的有效性为98.8%(95%CI 91.3-99.8%,P<0.0001),二价为97.5%(95%CI 90.0-99.4%,P<0.0001);九价对HPV 16/18/31/33/45/52/58持续感染的有效性为95.5%(95%CI 89.0-98.2%,P<0.0001)。未发生疫苗相关严重不良事件。

要点

  • 单剂九价HPV疫苗对HPV 16/18持续感染3年有效性98.8%(95%CI 91.3-99.8%)。
  • 单剂二价HPV疫苗对HPV 16/18持续感染3年有效性97.5%(95%CI 90.0-99.4%)。
  • 单剂九价对HPV 16/18/31/33/45/52/58持续感染3年有效性95.5%(95%CI 89.0-98.2%)。

核心结论

  • 接种3年后,单剂HPV疫苗高效、安全且提供持久保护。

研究设计与样本

  • 多中心随机双盲对照试验,纳入2275名15-20岁健康肯尼亚女性,随机分配至二价组(n=760)、九价组(n=758)或对照组(n=757)。
  • 主要结局为疫苗型别特异性宫颈HPV持续感染,主要评估在改良意向性治疗(mITT)HPV 16/18和HPV 16/18/31/33/45/52/58队列中进行优效性分析。

主要发现

  • HPV 16/18 mITT队列共检出75例持续感染:二价组2例、九价组1例、对照组72例。
  • 九价疫苗对HPV 16/18持续感染的有效性为98.8%(95%CI 91.3-99.8%,P<0.0001),二价为97.5%(95%CI 90.0-99.4%,P<0.0001)。
  • HPV 16/18/31/33/45/52/58 mITT队列共检出89例持续感染:九价组5例、对照组84例;九价疫苗有效性为95.5%(95%CI 89.0-98.2%,P<0.0001)。
  • 未发生疫苗相关严重不良事件。

关键数值与推荐

  • 试验达到预设的疫苗型别特异性持续HPV感染终点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cervical cancer burden is high where prophylactic vaccination and screening coverage are low. We demonstrated in a multicenter randomized, double-blind, controlled trial that single-dose human papillomavirus (HPV) vaccination had high vaccine efficacy (VE) against persistent infection at 18 months in Kenyan women. Here, we report findings of this trial through 3 years of follow-up. Overall, 2,275 healthy women aged 15-20 years were recruited and randomly assigned to receive bivalent (n = 760), nonavalent (n = 758) or control (n = 757) vaccine. The primary outcome was incident-persistent vaccine type-specific cervical HPV infection. The primary evaluation was superiority analysis in the modified intention-to-treat (mITT) HPV 16/18 and HPV 16/18/31/33/45/52/58 cohorts. The trial met its prespecified end points of vaccine type-specific persistent HPV infection. A total of 75 incident-persistent infections were detected in the HPV 16/18 mITT cohort: 2 in the bivalent group, 1 in the nonavalent group and 72 in the control group. Nonavalent VE was 98.8% (95% CI 91.3-99.8%, P < 0.0001) and bivalent VE was 97.5% (95% CI 90.0-99.4%, P < 0.0001). Overall, 89 persistent infections were detected in the HPV 16/18/31/33/45/52/58 mITT cohort: 5 in the nonavalent group and 84 in the control group; nonavalent VE was 95.5% (95% CI 89.0-98.2%, P < 0.0001). There were no vaccine-related severe adverse events. Three years after vaccination, single-dose HPV vaccination was highly efficacious, safe and conferred durable protection. ClinicalTrials.gov no. NCT03675256 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Barnabas RV, Brown ER, Onono MA, et al. Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results. Nat Med. 2023. PMID: 38049621. doi:10.1038/s41591-023-02658-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。